References of "Calcified Tissue International"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailPrediction of Bone Loss Rate in Healthy Postmenopausal Women
Reginster, Jean-Yves ULg; Deroisy, Rita ULg; Collette, Julien ULg et al

in Calcified Tissue International (1997), 60(3), 261-4

Prevention of fractures is the only way to drastically reduce osteoporosis-related health expenditures. In order to optimize the cost/benefit ratio of a strategy of prevention, it is essential to identify ... [more ▼]

Prevention of fractures is the only way to drastically reduce osteoporosis-related health expenditures. In order to optimize the cost/benefit ratio of a strategy of prevention, it is essential to identify, as early as possible, women who will develop fractures later in their life. Therefore, and since postmenopausal bone loss is an asymptomatic process, screening procedures should detect, at the time of the menopause, women whose postmenopausal bone loss is higher than the mean, and will, a couple of years later, exhibit a low mineral content and a subsequent high risk for fractures. For 3 years we have followed a cohort of 92 healthy women who had undergone menopause less than 36 months previously. By a multivariate discriminant analysis based on the differences in lumbar bone density, assessed by dual photon absorptiometry, and in a few routine biochemical parameters (serum phosphorus, estrone, androstenedione, and urine calcium) observed during the first 6 months of the study, we have been able to correctly predict the rate of spinal bone loss, observed at the end of the 3 years, in 76% of the subjects. All of the women who presented a bone loss higher than 10% over the 3 years were correctly isolated by our discriminant functions after 6 months of follow-up. We conclude that a measurement of lumbar bone mineral density coupled with a few routine biochemical determinations, repeated twice at a 6-month interval in healthy postmenopausal women, can isolate 100% of postmenopausal "fast bone losers" with an overall specificity of 76%. [less ▲]

Detailed reference viewed: 20 (5 ULg)
Full Text
Peer Reviewed
See detailDesign for an Ipriflavone Multicenter European Fracture Study
Reginster, Jean-Yves ULg; Bufalino, L.; Christiansen, C. et al

in Calcified Tissue International (1997), 61(Suppl 1), 28-32

In order to investigate the efficacy of ipriflavone (i.p.) on the prevention of vertebral fractures and the effect on bone mineral density (BMD) in women with postmenopausal osteoporosis, a large ... [more ▼]

In order to investigate the efficacy of ipriflavone (i.p.) on the prevention of vertebral fractures and the effect on bone mineral density (BMD) in women with postmenopausal osteoporosis, a large multicentric European study was designed and is presently ongoing. Included in the study were 460 Caucasian, nonobese postmenopausal women aged > 45 and < 75 years, menopaused for at least 12 months. Inclusion was on the basis of a lumbar bone mineral density (BMD) lower than 2 SD compared with healthy women aged 50 years, corresponding to values below 0.860 g/cm2 (antero-posterior measurement) by Hologic QDR 1000. Women with prevalent vertebral fractures were excluded as well as those presenting secondary osteoporosis or having been treated with medications that could affect bone metabolism. This study was designed as a 3-year, double-blind, placebo-controlled, parallel group study that randomized the women to the oral administration of either 3 x 200 mg/day of i.p. or placebo. All patients received a daily supplement of 500 mg calcium. The primary purpose of the study was to evaluate the efficacy of i.p. in preventing vertebral nontraumatic fractures. Fracture is defined here as a > or = 20% decrease in any anterior, central, or posterior T4-L4 vertebral height. Blinded vertebral X-ray readings and vertebral morphometry have been centralized in an independent Center, with standardized evaluation of two experts. Power calculations have been based on the hypothesis that 21% of placebo-treated patients would fracture within 3 years and that treatment with i.p. would lead to a 50% reduction in the incidence of fracture. Statistical tests have been designed to have a power of 80%, with a type I error equal to 5%. Secondary endpoints were changes in vertebral, radial, and femoral BMD. Centralized controls on 100% BMD scans would ensure the good quality of BMD readings. This study should verify the hypothesis that i.p. significantly decreases the risk of vertebral fracture in postmenopausal, osteoporotic women. [less ▲]

Detailed reference viewed: 8 (3 ULg)
Full Text
Peer Reviewed
See detailGREES recommendations for the Registration of new drugs in the prevention and treatment of osteoporosis
Reginster, Jean-Yves ULg; Compston, J

in Calcified Tissue International (1997), 60

Detailed reference viewed: 9 (2 ULg)
Full Text
Peer Reviewed
See detailDiagnostic efficiency of a self-evaluating risk assessment for postmenopausal osteoporosis
Goemaere, S; Zegels, Brigitte ULg; Toye, K et al

in Calcified Tissue International (1997), 61

Detailed reference viewed: 16 (4 ULg)
Full Text
Peer Reviewed
See detailDirect social costs of Osteoporotice hip fractures in Belgium
Gillet, Pierre ULg; Gosset, Christiane ULg; Reginster, Jean-Yves ULg

in Calcified Tissue International (1997), 61

Detailed reference viewed: 32 (8 ULg)
Full Text
Peer Reviewed
See detailOsteoporosis : The interest of a prospective vision
Gillet, Pierre ULg; Gosset, Christiane ULg; Reginster, Jean-Yves ULg

in Calcified Tissue International (1997), 61

Detailed reference viewed: 16 (9 ULg)
Full Text
Peer Reviewed
See detailRecommendations for the registration of agents used in the prevention and treatment of glucocorticoid-induced osteoporosis
Compston, JE; Audran, M; Avouac, B et al

in Calcified Tissue International (1996), 59

Detailed reference viewed: 11 (1 ULg)
Full Text
Peer Reviewed
See detailPrevention of Postmenopausal Bone Loss by Rectal Calcitonin
Reginster, Jean-Yves ULg; Jupsin, Isabelle ULg; Deroisy, Rita ULg et al

in Calcified Tissue International (1995), 56

A group (150) of healthy women, who had been menopausal for less than 5 years and who had never received any form of treatment to prevent bone loss were entered into a randomized, controlled study ... [more ▼]

A group (150) of healthy women, who had been menopausal for less than 5 years and who had never received any form of treatment to prevent bone loss were entered into a randomized, controlled study comprising three arms. They were randomly allocated to the double-blind administration of five suppositories per week containing either 100 IU of salmon calcitonin or a placebo, or to a group receiving a suppository containing 200 IU of salmon calcitonin three times per week. All women received 500 mg/day of calcium supplementation. After 12 months, bone mineral density (BMD) of the spine, measured by dual energy X-ray absorptiometry, decreased significantly (P < 0.01) in the placebo group by 3.1% (SD: 3.6%) but did not change in the two calcitonin groups [+1.3% (3.5%) with 100 IU/day and +2.3% (4.0%) with 200 IU 3/week]. The differences in response between the placebo group and the two calcitonin groups were significant (P < 0.05), but the difference between the two regimens of calcitonin administration was not. No differences appeared among the three groups for the response at the level of the hip. Evolution of biochemical markers reflecting bone turnover did not differ significantly among groups. Nearly 40% of the women withdrew prematurely because of local (rectal or intestinal) intolerance to repetitive suppositories, with a nonsignificantly different frequency in the placebo or calcitonin groups. We conclude that rectal calcitonin might be an interesting preventive approach against trabecular postmenopausal bone loss but that long-term acceptability of suppositories should be evaluated in view of each patient's sensibility or cultural background. [less ▲]

Detailed reference viewed: 6 (2 ULg)
Full Text
Peer Reviewed
See detailInvestigation of the Relationship between Osteoporosis and the Collagenase Gene by Means of Polymorphism of the 5'upstream Region of This Gene
Thiry-Blaise, L. M.; Taquet, A. N.; Reginster, Jean-Yves ULg et al

in Calcified Tissue International (1995), 56

Osteoporosis is a slowly progressing disease resulting from an imbalance between bone accretion and degradation. As interstitial collagenase is a key enzyme in the degradation of bone matrix, we ... [more ▼]

Osteoporosis is a slowly progressing disease resulting from an imbalance between bone accretion and degradation. As interstitial collagenase is a key enzyme in the degradation of bone matrix, we investigated a possible relationship between the collagenase gene and osteoporosis. Analysis of an amplified genomic DNA fragment from -524 to +52 by denaturing gradient gel electrophoresis and sequencing allowed us to detect three dimorphic sites upstream of base -300, one of them leading to a BanI restriction site. None of the sites could be directly associated with osteoporosis. The allele frequencies of the three dimorphic sites were estimated. The interallelic ratios were high, thus providing new useful genetic markers for linkage analysis. When comparing these ratios in osteoporotic and nonosteoporotic subjects, no significant differences could be observed. [less ▲]

Detailed reference viewed: 3 (2 ULg)
Full Text
Peer Reviewed
See detailRecommendations for the registration of new chemical entities used in the prevention and treatment of osteoporosis
Reginster, Jean-Yves ULg; Compston, JE; Jones, EA et al

in Calcified Tissue International (1995), 57

Detailed reference viewed: 19 (2 ULg)
Full Text
Peer Reviewed
See detailEffect of Transdermal 17 Beta-Estradiol and Oral Conjugated Equine Estrogens on Biochemical Parameters of Bone Resorption in Natural Menopause
Reginster, Jean-Yves ULg; Christiansen, C.; Dequinze, B. et al

in Calcified Tissue International (1993), 53

OBJECTIVE: To evaluate and compare the effects or oral and transdermal estrogen replacement therapy on biochemical markers of bone resorption in early postmenopausal women. DESIGN: Controlled, randomized ... [more ▼]

OBJECTIVE: To evaluate and compare the effects or oral and transdermal estrogen replacement therapy on biochemical markers of bone resorption in early postmenopausal women. DESIGN: Controlled, randomized group comparison. SETTING: Outpatient clinic for menopausal women and research into osteoporosis. SUBJECTS: Sixty healthy women menopausal for less than 5 years and who had never received any medications interfering with bone metabolism. INTERVENTIONS: The 60 women were randomly allocated to 3 months therapy with either oral conjugated estrogens (0.625 mg/day) (n = 28) or transdermal estradiol (50 micrograms/day) (n = 32) in cyclical combination with medroxyprogesterone acetate (5 mg/day). MAIN OUTCOME MEASURES: Traditional (urinary calcium/creatinine and hydroxyproline/creatinine) and the new specific (urinary pyridinoline/creatinine and deoxypyridinoline/creatinine) markers of bone resorption were determined before and after 3 months of treatment. RESULTS: In both groups, circulating levels of estrone and estradiol were significantly (P < 0.001) increased during treatment. In women treated with oral conjugated equine estrogens, urinary calcium/creatinine and hydroxyproline/creatinine ratios were significantly (P < 0.05) reduced. Pyridinoline/creatinine ratio fell from 69.1 (4) [mean (SEM)] to 50 (4) mumol/mumol (P < 0.01) and deoxypyridinoline/creatinine ratio fell from 10.8 (1) [mean (SEM)] to 8.3 (0.8) mumol/mumol (P < 0.01). In the group treated with transdermal estradiol, urinary hydroxyproline/creatinine ratio was significantly (P < 0.05) reduced. Pyridinoline/creatinine ratio fell from 66.3 (4) [mean (SEM)] to 46.2 (3) mumol/mumol (P < 0.01) and deoxypyridinoline/creatinine ratio fell from 11.5 (1.5) [mean (SEM)] to 7.7 (0.6) mumol/mumol (P < 0.01). There were no differences between the evolution of the biochemical variables in the two groups. CONCLUSION: These results suggest that oral conjugated equine estrogens and transdermal estradiol, in the given doses, are equally effective in reducing postmenopausal bone resorption. [less ▲]

Detailed reference viewed: 4 (3 ULg)
Full Text
Peer Reviewed
See detailOral Tiludronate: a new perspective for prevention and treatment of postmenopausal osteoporosis
Reginster, Jean-Yves ULg; Ethgen, D; Barbier, A et al

in Calcified Tissue International (1993), 52(S2), 30

Detailed reference viewed: 7 (1 ULg)
Full Text
Peer Reviewed
See detailEfficacy and tolerance of a new formulation of oral tiludronate (tablet) in the treatment of Paget's disease of bone
Reginster, Jean-Yves ULg; Treves, R; Renier, JC et al

in Calcified Tissue International (1993), 52(S2), 82

Detailed reference viewed: 8 (2 ULg)
Full Text
Peer Reviewed
See detailHuman bone cells from abundant matrix in tridimentional culture
Franchimont, N; Bassleer, C; Reginster, Jean-Yves ULg et al

in Calcified Tissue International (1993), 52(S1), 10

Detailed reference viewed: 7 (1 ULg)
Full Text
Peer Reviewed
See detailEfficacy and tolerance of a new formulation of oral tiludronate (tablet) in the treatment of Paget's disease of bone
Reginster, Jean-Yves ULg; Treves, R; Renier, JC et al

in Calcified Tissue International (1993), 52(S1), 66

Detailed reference viewed: 10 (1 ULg)
Full Text
Peer Reviewed
See detailCalcitonin use in non osteoporotic diseases
Reginster, Jean-Yves ULg

in Calcified Tissue International (1993), 52(S1), 101

Detailed reference viewed: 9 (1 ULg)
Full Text
Peer Reviewed
See detailMinimal Levels of Serum Estradiol Prevent Postmenopausal Bone Loss
Reginster, Jean-Yves ULg; Sarlet, Nathalie ULg; Deroisy, Rita ULg et al

in Calcified Tissue International (1992), 51

Biochemical parameters reflecting bone resorption [urinary calcium/creatinine (Ca/Cr) and hydroxyproline/creatinine (OH/Cr)] were related to serum estrogens [estrone (E1) and estradiol (E2)] in 262 ... [more ▼]

Biochemical parameters reflecting bone resorption [urinary calcium/creatinine (Ca/Cr) and hydroxyproline/creatinine (OH/Cr)] were related to serum estrogens [estrone (E1) and estradiol (E2)] in 262 healthy women including 158 patients receiving estrogen replacement therapy (ERT) for at least 6 months, 49 eugonadal women, and 55 untreated postmenopausal women. A significant (P < 0.001) correlation exists between serum E2 and Ca/Cr: Ca/Cr (mg/dl) = -0.00044 E2 (pg/ml) + 0.129 (n = 262; r = -0.37), serum E2 and OH/Cr: (OH/Cr (mg/g) = -0.049 E2 (pg/ml) + 18.76 (n = 262; r = -0.36), serum E1 and Ca/Cr: Ca/Cr (mg/dl) = -0.0003 E1 (pg/ml) + 0.127 (n = 261; r = -0.28) but not between serum E1 and OH/Cr. Women with circulating levels of E2 between 60 and 90 pg/ml have a significant (P < 0.01) reduction of Ca/Cr and OH/Cr when compared with those with lower levels of E2. Higher values of E2 do not provide additional benefit. We conclude that in postmenopausal women receiving an estrogen replacement therapy (ERT), a significant reduction of bone resorption is achieved when circulating levels of estradiol reach a value (60 pg/ml) corresponding to the one measured, in eugonadal women, during the last days of the early follicular phase of the menstrual cycle. We suggest that oral or percutaneous ERT should induce a minimal value of 60 pg/ml to prevent postmenopausal bone loss. [less ▲]

Detailed reference viewed: 7 (3 ULg)
Full Text
Peer Reviewed
See detailEndogenous Production of Specific Antibodies Does Not Decrease Hypocalcemic Response to Calcitonin in Young Rabbits
Reginster, Jean-Yves ULg; Azria, M.; Lismonde, Stéphanie ULg et al

in Calcified Tissue International (1992), 50

In order to evaluate the potential inhibition of the acute anti-osteoclastic activity of salmon calcitonin (SCT) by specific antibodies (Ab), we compared the SCT-induced hypocalcemic effect in young male ... [more ▼]

In order to evaluate the potential inhibition of the acute anti-osteoclastic activity of salmon calcitonin (SCT) by specific antibodies (Ab), we compared the SCT-induced hypocalcemic effect in young male rabbits with significant titers of high affinity Ab and in matched animals without Ab. Immunization of rabbits was performed by repetitive s.c. injections of SCT and Freund adjuvant. Ab were present in four-fifths of SCT-treated rabbits (Ab+). Their titer varied from 0.8 x 10(-9) to 30 x 10(-9) M/liter and their constant of affinity from 0.97 x 10(9) to 4.2 x 10(9) L/M. Intravenous injection of 1 IU/kg SCT to Ab+ rabbits induced a significant decrease (P less than 0.01) of ionized serum calcium (Ca2+) after 30 minutes (mean +/- SD: -9 +/- 0.6%) and until the 240th minute of the test (-16.7 +/- 4.7%), with a maximum after 120 minutes (-22.6 +/- 2%). This was not significantly different from the hypocalcemic effect measured after the same procedure performed in matched animals without Ab (Ab-): significant decrease in Ca2+ (P less than 0.01) after 30 minutes (-8.2 +/- 2.2%), maximal after 150 minutes (-23.2 +/- 4.9%), and lasting until 210 minutes (-14.5 +/- 3.7%). We conclude that, in the particular model of the male young rabbit, specific anti-SCT Ab do not block or reduce the acute anti-osteoclastic activity of SCT. [less ▲]

Detailed reference viewed: 4 (2 ULg)